Pneumonia News and Research

Latest Pneumonia News and Research

Lung ultrasound helps predict clinical progression of severe COVID-19 patients

Lung ultrasound, considered a simple method for diagnosing lung disease, can also help predict the clinical progression of severe COVID-19 patients, according to a study conducted at the University of São Paulo's Medical School in São Paulo City, Brazil.

10 Feb 2021

Some COVID-19 patients experience persistent chronic fatigue six months after infection, finds study

Scientists from Germany recently revealed that almost 50% of patients present with moderate to severe chronic fatigue syndrome six months after SARS-CoV-2 infection.

10 Feb 2021

Research from Israel shows mRNA vaccine is ~50% effective in reducing severe cases

In a report published on the pre-print server medRxiv, researchers at The Hebrew University of Jerusalem, the University of Trento, and the Racah Institute of Physics suggest that the shape of the outbreak in patients over 60 years old has changed because of the vaccinations.

8 Feb 2021

COVID-19 pandemic and nanotechnology

Writing in the International Journal of Nanomedicine, Professor Dongki Yang, from the Department of Physiology, Gachon University, South Korea, has reviewed the available knowledge on the coronaviruses, current approaches to tackle the newly emerged SARS-CoV-2 infection, and the innovative application of nanotechnology in the COVID-19 pandemic.

8 Feb 2021

Anticancer drug may reduce mortality and speed up recovery for severe COVID-19 patients

Treating severe COVID-19 patients with the anticancer drug bevacizumab may reduce mortality and speed up recovery, according to a small clinical study in Italy and China that was led by researchers at Karolinska Institutet in Sweden between February and April 2020.

6 Feb 2021

Researchers develop systems to detect an atypical fungus responsible for severe pneumonia

The group led by Dr. Enrique J. Calderón - "Clinical Epidemiology and Vascular Risk" at the Institute of Biomedicine of Seville - IBiS/University Hospitals Virgen del Rocío and Macarena/CSIC/University of Seville, also a member of CIBERESP, participated in a project with researchers from CIBER-BBN, in which they developed systems to detect Pneumocystis jirovecii, an atypical fungus responsible for very severe pneumonia in immunosuppressed patients.

6 Feb 2021

Insight into role of aging in response to SARS-CoV-2 infection

Researchers at the University of California, Irvine set out to determine the differences between young people and older adults regarding their host responses against SARS-CoV-2. The team revealed that independent of disease severity, COVID-19 was linked to a significant shift in plasma inflammatory factors. The research is posted to the pre-print server medRxiv*.

3 Feb 2021

One dose of VSV-vectored vaccine prevents SARS-CoV-2 replication in hamsters

A new preprint research paper posted to the bioRxiv server describes a viral vector vaccine candidate's efficacy to protect against SARS-CoV-2 replication in a hamster model.

3 Feb 2021

Immune profiling shows differences in COVID-19 and influenza pathologic pathways

A study conducted at Johns Hopkins University School of Medicine in Baltimore has revealed distinct differences in the immune pathways that are activated by infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and those that are activated by influenza.

2 Feb 2021

Study shows link between periodontitis and COVID-19 complications

COVID-19 patients are at least three times more likely to experience complications if they also have gum disease, according to research published today in the Journal of Clinical Periodontology, the official publication of the European Federation of Periodontology.

2 Feb 2021

Could ultra-low dose radiotherapy treat COVID-19-related pneumonia?

Researchers at the Department of Radiation Oncology, La Milagrosa Hospital, GenesisCare, Madrid, Spain, showed the potential benefit of treating COVID-19 pneumonia with ultra-low doses of radiotherapy.

2 Feb 2021

Johnson & Johnson SARS-CoV-2 vaccine shows promise in clinical trials

A new study shows that a single immunization with a low dose of the Ad26.COV2.S vaccine – also known as the ‘Johnson & Johnson vaccine’ – effectively protected against SARS-CoV-2 challenge in rhesus macaques.

2 Feb 2021

Can metformin reduce mortality in diabetic individuals with severe COVID-19?

A new study by researchers in China and the U.S. describes a round-up of the effects of commonly used hypoglycemic drugs on the outcomes of COVID-19 in diabetic patients.

1 Feb 2021

Colchicine may have therapeutic potential against COVID-19

A new study describes the results of colchicine in mitigating the inflammatory storm associated with COVID-19, and thus preventing a percentage of severe and critical cases.

1 Feb 2021

Inhaled single dose vaccine creates antibodies and prevents infection in rhesus macaques

Now, a new preprint research paper describes a chimpanzee adenovirus-vectored vaccine that, when administered intranasally in rhesus macaques, led to a robust immune response and demonstrated protection against infection by the virus that causes COVID-19, namely, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The preprint is published on the bioRxiv server.

1 Feb 2021

Complication of severe SARS-CoV-2 pneumonia results in persistent cortical blindness: Case report

A study recently published in the journal Cureus has described a case report of a coronavirus disease 2019 (COVID-19) patient who presented with pneumonia, posterior reversible encephalopathy syndrome (PRES), and persistent cortical blindness. A detailed clinical presentation of the patient is provided in the report.

31 Jan 2021

DSMB recommends continuation of Phase 2/3 study of opaganib for severe COVID-19

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that the independent Data Safety Monitoring Board (DSMB) for the global Phase 2/3 study of opaganib in patients with severe COVID-19, unanimously recommended to continue the study following a pre-scheduled futility review of unblinded efficacy data from the first 135 patients treated in the study and safety data from the first 175 patients.

30 Jan 2021